"FDA Approves Dexcom Stelo as First OTC Continuous Glucose Monitor"
The FDA has cleared Dexcom to sell the Stelo, a continuous glucose monitor, over-the-counter to adults without insulin dependence, with the product set to launch this summer. The device is designed for people with type 2 diabetes and those without diabetes who want to monitor their blood sugar levels. Paired with a smartphone app, it provides glucose measurements every 15 minutes. This move marks a significant expansion in access to continuous glucose monitoring technology, which has become a lucrative market for companies like Dexcom and Abbott.
